Tethys Bioscience Obtains $33,000,000 New Funding

  • Feed Type
  • Date
  • Company Name
    Tethys Bioscience
  • Mailing Address
    5858 Horton Street Emeryville, CA 94608
  • Company Description
    The company has become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: Biomarkers. The company believes there is a large unmet need in both the discovery of potentially important biomarkers and the eventual use of them in routine clinical practice for many significant diseases.
    Tethys has built expertise, created significant intellectual property, and is executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and Value Creation. Tethys is focused upon biomarkers that yield significant savings to the health care system and improve the quality of life for patients.
  • Website
  • Transaction Type
    Debt, Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    These proceeds will support expanded commercialization of the Tethys PreDx™ Diabetes Risk Score (DRS), a simple-to-use, multimarker blood test that enables accurate identification of patients who have a high risk of developing type 2 diabetes within five years.
  • M&A Terms
  • Venture Investor
    Greenspring Associates
  • Venture Investor
    Aeris Capital AG
  • Venture Investor
    Mohr Davidow Ventures
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    Wasatch Funds
  • Venture Investor
    Oxford Finance Corporation
  • Venture Investor
    Silicon Valley Bank

Trending on Xconomy